

MANUSCRIPTS (16)

2021

Treatment Patterns

- Lee HC, Ailawadhi S, Gasparetto CJ, et al. Treatment patterns and outcomes in elderly patients with newly diagnosed multiple myeloma: results from the Connect MM Registry. *Blood Cancer J* 2021;11(7):134.

Baseline Disease Characteristics

- Gasparetto C, Jagannath S, Rifkin RM, et al. Effect of t (11;14) Abnormality on Outcomes of Patients With Newly Diagnosed Multiple Myeloma in the Connect MM Registry. *Clinical Lymphoma Myeloma and Leukemia*. August 2021. doi:10.1016/j.clml.2021.08.007

2020

Health-Related Quality of Life

- Abonour R, Rifkin RM, Gasparetto C, et al. Effect of initial treatment on health-related quality of life in patients with newly diagnosed multiple myeloma without immediate stem cell transplant intent: results from the Connect® MM Registry. *Br J Haematol*. 2021;193(1):93-100.

Treatment Patterns

- Ailawadhi S, Jagannath S, Lee HC, et al. Association of Race With Treatment Patterns and Survival Outcomes: A Connect® MM Registry Analysis. *Cancer*. 2020;126(19):4332-4340.

2019

Baseline Disease Characteristics

- Ailawadhi S, Jagannath S, Narang M, et al. Connect MM Registry as a national reference for United States multiple myeloma patients. *Cancer Med*. 2020;9(1):35-42.

Prognostic Models

- Terebelo HR, Abonour R, Gasparetto CJ, et al. Development of a prognostic model for overall survival in multiple myeloma using the Connect® MM Patient Registry. *Br J Haematol*. 2019;187(5):602-614.

Treatment Patterns

- Jagannath S, Rifkin RM, Gasparetto CJ, et al. Treatment journeys of newly diagnosed multiple myeloma (NDMM) patients: results from the Connect® MM Registry. *Clin Lymphoma Myeloma Leuk*. 2020;20(5):272-276.

2018

Maintenance

- Abonour R, Wagner L, Durie BGM, et al. Impact of post-transplantation maintenance therapy on health-related quality of life in patients with multiple myeloma: data from the Connect[®] MM Registry. *Ann Hematol.* 2018;97(12):2425-2436.
- Jagannath S, Abonour R, Durie, BGM, et al. Impact of post-ASCT maintenance therapy on outcomes in patients with newly diagnosed multiple myeloma in Connect MM. *Blood Adv.* 2018;2(13):1608-1615.
- Rifkin RM, Jagannath S, Durie BGM, et al. Treatment Outcomes and Health Care Resource Utilization in Patients with Newly Diagnosed Multiple Myeloma Receiving Lenalidomide-Only Maintenance, Any Maintenance, or No Maintenance: Results from the Connect MM Registry. *Clin Ther.* 2018;40:1193-1202.e1

SPM

- Jagannath S, Abonour R, Durie, BGM, et al. Heterogeneity of second-line treatment for patients with multiple myeloma in the Connect[®] MM Registry (2010–2016). *Clin Lymphoma Myeloma Leuk.* 2018;18(7):480-485.

2017

Prognostic Models

- Terebello H, Srinivasan S, Narang M, et al. Recognition of early mortality in multiple myeloma by a prediction matrix. *American J Hematology.* 2017;92:915–923.

RCT Eligibility Criteria

- Shah JJ, Abonour R, Gasparetto C, et al. Analysis of Common Eligibility Criteria of Randomized Controlled Trials in Newly Diagnosed Multiple Myeloma Patients and Extrapolating Outcomes. *Clinical Lymphoma Myeloma Leukemia.* 2017;9:575-583.

2016

SPM

- Rifkin RM, Abonour R, Shah JJ et al. Connect MM[®] – the Multiple Myeloma Disease Registry: incidence of second primary malignancies in patients treated with lenalidomide. *Leukemia & Lymphoma.* 2016;2016;57(9): 2228-2231.

2015

Baseline Disease Characteristics

- Rifkin RM, Abonour R, Terebello H et al. Connect MM[®] Registry: The Importance of Establishing Baseline Disease Characteristics. *Clinical Lymphoma Myeloma Leukemia.* 2015;15:368-376.

ORAL PRESENTATIONS (6)

2021

Disease Burden

- Tang D, Hari P, Ramasamy K et al. Real-World Treatment Patterns and Clinical, Economic, and Humanistic Burden in Triple-Class Refractory Multiple Myeloma: Analysis of the CONNECT® Multiple Myeloma (MM) Disease Registry. 63rd ASH Annual Meeting and Exposition. Dec 2021

2019

Health-Related Quality of Life

- Abonour R, Rifkin RM, Gasparetto C, et al. Impact of Initial Treatment on HRQoL and Outcomes in Patients with Newly Diagnosed Multiple Myeloma without Intent for Immediate Transplant: Results from the CONNECT® MM Registry. Proceedings from the 44th Annual Meeting of the Japanese Society of Myeloma, May 11-12, 2019; Aichi Prefecture, Japan. Abstract PL2-3.

2018

Health-Related Quality of Life

- Abonour R, Rifkin RM, Gasparetto C, et al. Impact of Initial Treatment on HRQoL and Outcomes in Patients with Newly Diagnosed Multiple Myeloma without Intent for Immediate Transplant: Results from the CONNECT® MM Registry. Proceedings from the European Society for Medical Oncology 2018 Meeting; October 19-23, 2018; Munich, Germany. Abstract 10070.
- Wagner LI, Durie BGM, Jagannath S, et al. Health-Related Quality Of Life Assessments Predict Relapse Or Death In Patients With Newly Diagnosed Multiple Myeloma: Results From The Connect® MM Registry. Proceedings from the International Society for Pharmacoeconomics and Outcomes Research Conference; May 19-23, 2018; Baltimore, MD. Abstract CN3.

2017

Treatment Patterns

- Rifkin RM, Abonour R, Durie BGM, et al. Treatment Patterns from 2009 to 2015 in Patients with Newly Diagnosed Multiple Myeloma in the United States: A Report from the Connect® MM Registry. *Clin Lymphoma Myeloma Leuk.* 2017;17(suppl 1):e20-e21.

2016

Maintenance

- Abonour R, Durie BGM, Jagannath S, et al. Health-Related Quality of Life of Patients with Newly Diagnosed Multiple Myeloma Receiving Any or Lenalidomide Maintenance after Autologous Stem Cell Transplant in the Connect® MM Disease Registry. *Blood.* 2016;128(22):537.

POSTERS (47)

2021

- Wagner L, Abonour R, Ailawadhi S et al. Health-Related Quality of Life (HRQL) Among Real-World Ide-Cel-Eligible Patients (pts) With Relapsed/Refractory Multiple Myeloma (RRMM): Results From the Connect MM Registry. Presented at the 18th International Myeloma Workshop, September 8-11, 2021.

2020

Baseline Disease Characteristics

- Ailawadhi S, Lee HC, Omel J, et al. Impact of lenalidomide-bortezomib-dexamethasone (RVd) induction on patients with newly diagnosed multiple myeloma and renal impairment: Results from the Connect MM Registry. *J Clin Oncol*. 2020;38:(suppl; abstr 8518).
- La L, Jagannath S, Ailawadhi S, et al. Clinical Features and Survival Outcomes in Diabetic Patients with Newly Diagnosed Multiple Myeloma (NDMM) Enrolled in the Connect[®] MM Registry. *Blood*. 2020;136 (Supplement 1): 49–50.

Health-Related Quality of Life

- Wagner LI, Toomey K, Ailawadhi S, et al. Clinical Outcomes and Health-Related Quality of Life (HRQoL) Among Randomized Clinical Trial (RCT)-Eligible and RCT-Ineligible Patients: Results From the Connect[®] MM Registry. *HemaSphere*, 2020;4:S1. Abstract EP1005.

Treatment Patterns

- Lee HC, Ailawadhi S, Gasparetto CJ, et al. Treatment Patterns and Survival Outcomes of Elderly Patients With Newly Diagnosed Multiple Myeloma: Results From the Connect[®] MM Registry. *HemaSphere*, 2020;4:S1. Abstract EP997.

2019

RCT Eligibility Criteria

- Wagner LI, Toomey K, Ailawadhi S, et al. Clinical Outcomes and Health-Related Quality of Life Among Randomized Clinical Trial (RCT)-Eligible and RCT-Ineligible Patients: Results From the Connect[®] MM Registry. *Blood* (2019) 134 (Supplement_1): 1843.

Treatment Patterns

- Lee HC, Ailawadhi S, Gasparetto CJ, et al. Treatment Patterns and Outcomes in Elderly Patients With Newly Diagnosed Multiple Myeloma: Results From the Connect MM[®] Registry. *Blood* (2019) 134 (Supplement_1): 3129.

Baseline Disease Characteristics

- Gasparetto CJ, Jagannath S, Rifkin RM, et al. Effect of t(11;14) on Outcomes of Patients With Newly Diagnosed Multiple Myeloma in the Connect[®] MM Registry. *Clin Lymphoma Myeloma Leuk*. 2019;19(10_supplement):E74-E75.
- Ailawadhi S, Gasparetto CJ, Jagannath S, et al. Frequency of and Associations Amongst Baseline Cytogenetics in Patients With Newly Diagnosed Multiple Myeloma in the Connect[®] MM Registry. *Clin Lymphoma Myeloma Leuk*. 2019;19(10_supplement):E75.
- Gasparetto CJ, Jagannath S, Rifkin RM, et al. Effect of t(11;14) on Outcomes of Patients with Newly Diagnosed Multiple Myeloma in the Connect[®] MM Registry. *J Clin Oncol* 37, 2019 (15_suppl; abstr 8032).

Maintenance

- Jagannath S, Narang M, Ailawadhi S, et al. Treatment Choices and Outcomes for Patients With Multiple Myeloma After Relapse on Lenalidomide Maintenance Therapy: Results From the Connect® MM Registry. *HemaSphere*. 2019;3:634.
- Jagannath S, Narang M, Ailawadhi S, et al. Connect® MM Registry: Treatment Choices and Outcomes for Patients With Multiple Myeloma After Relapse on Lenalidomide Maintenance Therapy. Proceedings from the 44th Annual Meeting of the Japanese Society of Myeloma, May 11-12, 2019; Aichi Prefecture, Japan. Abstract 9003.

Treatment Patterns

- Jagannath S, Rifkin RM, Gasparetto CJ, et al. Development of a Predictive Model of Multiple Myeloma Patient Outcomes Based on Treatment Sequencing Using the Connect® MM Patient Registry. Proceedings from the 44th Annual Meeting of the Japanese Society of Myeloma, May 11-12, 2019; Aichi Prefecture, Japan. Abstract 9002.

2018

Maintenance

- Jagannath S, Narang M, Sikander A, et al. Treatment Choices and Outcomes for Patients With Multiple Myeloma After Relapse on Lenalidomide Maintenance Therapy: Results From the Connect® MM Registry. Proceedings from the 2018 American Society of Hematology Meeting; December 1-4, 2018; San Diego, California. Abstract 3232.

Prognostic Models

- Gasparetto CJ, Rifkin RM, Terebelo HR, et al. Predictors of Long-Term Survival in Newly Diagnosed Multiple Myeloma (NDMM) Patients Enrolled in the Connect® MM Registry. *J Clin Oncol* 36, 2018 (suppl; abstr 8037).

Treatment Patterns

- Jagannath S, Rifkin RM, Gasparetto CJ, et al. Treatment Journeys in Newly Diagnosed Multiple Myeloma (NDMM) Patients: Results From the Connect® MM Registry. *J Clin Oncol* 36, 2018 (suppl; abstr 8041).
- Jagannath S, Rifkin RM, Gasparetto C, et al. Development Of A Predictive Model Of Multiple Myeloma (MM) Patient Outcomes Based On Treatment (Tx) Sequencing Using Data From The Connect® MM Patient Registry. *HemaSphere*, 2018;2:S1, Abstract n. PF570.

2017

Baseline Disease Characteristics

- Gasparetto C, Abonour R, Jagannath S, et al. Differential Effect of t(11;14) Abnormality on Survival and Depth of Response in African American (AA) and Non-AA (NAA) Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) in the Connect® MM Registry. *Blood*. 2017;130(suppl 1):3101.
- Gasparetto CJ, Rafat Abonour R, Jagannath S et al. The Connect MM Registry: Impact of the Cytogenetic Abnormality t(11;14) on Survival Outcomes in African American And Non-AA Patients With Newly Diagnosed Multiple Myeloma. Proceedings from the 22nd Congress of the European Hematology Association; June 23, 2017; Madrid, Spain. Abstract P349.
- Gasparetto CJ, Abonour R, Jagannath S. Impact of t(11;14) on Outcomes in African American (AA) and Non-AA (NAA) Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Connect® MM Registry. *J Clin Oncol*. 2017;35(suppl 15):8023.

- Narang M, Abonour R, Durie BGM, et al. Baseline Disease Characteristics and Diagnostic Patterns for NDMM of the Connect® MM Registry: Observations over Time in Cohort 1 (2009-2011) and Cohort 2 (2012-2016). *Blood*. 2017;130(suppl 1):3156.

Treatment Patterns

- Jagannath S, Rifkin RM, Gasparetto C, et al. Development of a Predictive Model of Multiple Myeloma (MM) Patient (pt) Outcomes Based on Treatment Class Transitions Using the Connect® MM Patient Registry. *Blood*. 2017;130(suppl 1):3122.

Prognostic Models

- Terebelo H, Abonour R, Gasparetto C, et al. Development of a Prognostic Model That Predicts 3- and 5-Year Overall Survival in Multiple Myeloma Using the Connect® MM Patient Registry. *Blood*. 2017;130(suppl 1):1842.

Maintenance

- Jagannath S, Abonour R, Durie BGM, et al. Impact of Post-autologous Stem Cell Transplant (ASCT) Maintenance Therapy on Outcomes in Patients (Pts) With Newly Diagnosed Multiple Myeloma (NDMM) Using The Large Prospective Community-based Connect® MM Registry. Proceedings from the 22nd Congress of the European Hematology Association; June 22-25, 2017; Madrid, Spain. Abstract E1239.
- Jagannath S, Abonour R, Durie BGM et al. Impact of Post-Autologous Stem Cell Transplant (ASCT) Maintenance Therapy on Outcomes in Patients (Pts) With Newly Diagnosed Multiple Myeloma (NDMM) Using the Large Prospective Community-Based Connect® MM Registry. *J Clin Oncol*. 2017;35(suppl 15):8040.
- Rifkin RM, Jagannath S, Durie BGM, et al. Analysis of The Connect MM Registry: Treatment Outcomes and Healthcare Resource Utilization in Patients With Newly Diagnosed Multiple Myeloma Who Received Lenalidomide Maintenance or No Maintenance. Proceedings from the 22nd Congress of the European Hematology Association; June 22-25, 2017; Madrid, Spain. Abstract E1277.
- Abonour R, Durie BGM, Jagannath S, et al. Health-Related Quality of Life (HRQoL) of Patients (pts) With Newly Diagnosed Multiple Myeloma (NDMM) Receiving Any or Lenalidomide (LEN) Maintenance After Autologous Stem Cell Transplant (ASCT) in the Connect® MM Disease Registry. *Clin Lymphoma Myeloma Leuk*. 2017;17(suppl 1):e89-e90.

2016

Treatment Patterns

- Rifkin RM, Abonour R, Durie BGM, et al. Treatment Patterns from 2009 to 2015 in Patients with Newly Diagnosed Multiple Myeloma in the United States: A Report from the Connect® MM Registry. *Blood*. 2016;128(22):4489.

2015

Treatment Patterns

- Shah JJ, Abonour R, Narang M, et al. Clinical Outcomes of Patients with Newly Diagnosed Multiple Myeloma Receiving Triplet Therapy in the Connect MM® Disease Registry. *Blood*. 2015;126(23):4229.

Baseline Disease Characteristics

- Shah JJ, Narang M, Abonour R, et al. Clinical Outcomes in Patients With Newly Diagnosed Multiple Myeloma and t(4;14) in the Connect MM® Registry. Proceedings from the 15th International Myeloma Workshop (IMW); Rome, Italy; 2015. Abstract O-102.
- Shah JJ, Abonour R, Mehta J, et al. Overall survival in newly diagnosed MM patients with del(17p): a report from the Connect® MM Registry. *J Clin Oncol*. 2015;33(suppl 15):8582.

2014

Baseline Disease Characteristics

- Shah JJ, Abonour R, Durie BGM et al. Connect MM®—the Multiple Myeloma (MM) Disease Registry: Interim Analysis of Overall Survival and Outcomes in Patients with High-Risk Disease. *Blood*. 2014;124(21):2106.

2013

Treatment Patterns

- Abonour R, Shah J, Durie B, et al. Response to first-line treatment in stem cell transplant (SCT) and non-SCT patients with newly diagnosed multiple myeloma who are enrolled in the Connect MM registry. *Blood*. 2013;122(21):3207.

Health-Related Quality of Life

- Pashos CL, Shah JJ, Terebello HR, et al. Change in patient-reported outcomes during the first year post-diagnosis of multiple myeloma. *Value in Health*. 2013;16:A146.
- Pashos CL, Shah JJ, Terebello HR, et al. Changes in patient-reported outcomes in patients diagnosed with and treated for multiple myeloma in the Connect MM registry. *Blood*. 2013;31(suppl 15):8586.
- Pashos CL, Shah JJ, Terebello HR, et al. Changes in patient-reported outcomes in patients diagnosed with and treated for multiple myeloma in the Connect MM registry. *J Clin Oncol*. 2013;31(15):7086.
- Pashos CL, Shah JJ, Terebello HR, et al. Change in patient-reported outcomes in the first year post-diagnosis of multiple myeloma (MM) in CONNECT MM. *Clin Lymphoma Myeloma*. 2013;13(suppl 1):S218.

Other

- Shah JJ, Terebello HR, Durie BGM, et al. Characterization of death ≤ 6 months of enrollment for newly diagnosed multiple myeloma in the Connect MM US Registry. *Clin Lymphoma Myeloma*. 2013;13(Suppl 1):S241.

2012

Health-Related Quality of Life

- Pashos CL, Durie BGM, Rifkin RM, et al. Association of health-related quality of life among patients with multiple myeloma with insurance coverage. *Value Health*. 2012;15(4):A233-A324.
- Toomey K, Durie BGM, Rifkin RM, et al. Variation of health-related quality of life by gender among patients newly diagnosed with multiple myeloma. Proceedings from the Multinational Association of Supportive Care in Cancer. New York, NY; 2012. Abstract 1103.

2011

Health-Related Quality of Life

- Pashos CL, Durie BGM, Rifkin RM, et al. Association of health-related quality of life (HRQOL) with bone disease in multiple myeloma. Proceedings from the 13th International Myeloma Workshop. Paris, France; 2011. Abstract P-378.
- Pashos CL, Durie BGM, Mehta J, et al. Association of health-related quality of life with bone disease in multiple myeloma. Proceedings from the Lymphoma & Myeloma International Congress. New York, NY; 2011. Abstract P-26.
- Pashos CL, Durie BGM, Mehta J, et al. Association of health-related quality of life (HRQOL) with ISS stage and ECOG status in multiple myeloma. *Value in Health*. 2011;14(3):A175-A176.
- Pashos CL, Durie BGM, Rifkin RM, et al. Variation in health-related quality of life (HRQOL) among multiple myeloma patients by insurance coverage. *Blood*. 2011;118(21)3150.
- Pashos CL, Durie BGM, Rifkin R, et al. Association of race and health-related quality of life (HRQOL) among multiple myeloma patients. *Blood*. 2011;118(21)5070.

2010

Baseline Disease Characteristics

- Durie BGM, Shah JJ, Abonour R, et al. New US myeloma registry (Connect MM-the multiple myeloma disease registry): features of newly diagnosed patients in 2010. *Blood*. 2010;116(21):5032.

Health-Related Quality of Life

- Pashos CL, Durie BGM, Rifkin RM, et al. Variation in health-related quality of life (HRQOL) by ISS stage and ECOG status among multiple myeloma patients. *Blood*. 2011;116(21)3828.

ABSTRACTS (3)

2018

None

2017

Maintenance

- Rifkin R, Abonour R, Durie BGM et al. Treatment Outcomes and Healthcare Resource Utilization (HRU) in Patients (Pts) With Newly Diagnosed Multiple Myeloma (NDMM) With Lenalidomide (LEN) Only or No Maintenance: Connect[®] MM Registry. *J Clin Oncol.* 2017;35:e19527.

2016

None

2015

Baseline Disease Characteristics

- Toomey K, Gasparetto CJ, Shah JJ, et al. Characteristics and survival of African American (AA) newly diagnosed multiple myeloma (NDMM) Patients (Pts): a report from the Connect[®] MM Registry. *J Clin Oncol.* 2015;33:e19529.

2014

None

2013

None

2012

Health-Related Quality of Life

- Pashos CL, Durie BG, Rifkin RM, et al. Association of race and health-related quality of life among patients newly diagnosed with multiple myeloma. *J Clin Oncol.* 2012;30:e18556.

2011

None

2010

None